TY - JOUR
T1 - Evidence for cortical inhibitory and excitatory dysfunction in obsessive compulsive disorder
AU - Richter, Margaret A
AU - de Jesus, Danilo R
AU - Hoppenbrouwers, Sylco
AU - Daigle, Melissa
AU - Deluce, Jasna
AU - Ravindran, Lakshmi N
AU - Fitzgerald, Paul Bernard
AU - Daskalakis, Zafiris Jeff
PY - 2012
Y1 - 2012
N2 - Several lines of evidence suggest that obsessive-compulsive disorder (OCD) is associated with an inability to inhibit unwanted intrusive
thoughts. The neurophysiological mechanisms mediating such inhibitory deficits include abnormalities in cortical g-aminobutyric acid
(GABA) inhibitory as well as N-methyl-D-aspartate (NMDA) receptor-mediated mechanisms. Molecular evidence suggests that both
these neurotransmitter systems are involved in OCD. Transcranial magnetic stimulation (TMS) represents a noninvasive technique to
ascertain neurophysiological indices of inhibitory GABA and facilitatory NMDA receptor-mediated mechanisms. In this study, both
mechanisms were indexed in 34 patients with OCD (23 unmedicated and 11 medicated) and compared with 34 healthy subjects.
Cortical inhibitory and facilitatory neurotransmission was measured using TMS paradigms known as short-interval cortical inhibition
(SICI), cortical silent period (CSP), and intracortical facilitation (ICF). Patients with OCD demonstrated significantly shortened CSP
(po0.001, Cohen?s d ? 0.91) and increased ICF (po0.009, Cohen?s d ? 0.71) compared with healthy subjects. By contrast, there were
no significant deficits in SICI. After excluding patients with OCD and comorbid major depressive disorder (MDD) from the analysis, these
differences remained significant. Our findings suggest that OCD is associated with dysregulation in cortical inhibitory and facilitatory
neurotransmission. Specifically, these findings suggest impairments in GABAB receptor-mediated and NMDA receptor-mediated
neurotransmission. These findings are consistent with previously published genetic studies implicating GABAB, and NMDA transporter
and receptor genes in OCD. It is posited that dysregulation of such mechanisms may lead to the generation and persistence of intrusive
thoughts that form the basis for this disorder
AB - Several lines of evidence suggest that obsessive-compulsive disorder (OCD) is associated with an inability to inhibit unwanted intrusive
thoughts. The neurophysiological mechanisms mediating such inhibitory deficits include abnormalities in cortical g-aminobutyric acid
(GABA) inhibitory as well as N-methyl-D-aspartate (NMDA) receptor-mediated mechanisms. Molecular evidence suggests that both
these neurotransmitter systems are involved in OCD. Transcranial magnetic stimulation (TMS) represents a noninvasive technique to
ascertain neurophysiological indices of inhibitory GABA and facilitatory NMDA receptor-mediated mechanisms. In this study, both
mechanisms were indexed in 34 patients with OCD (23 unmedicated and 11 medicated) and compared with 34 healthy subjects.
Cortical inhibitory and facilitatory neurotransmission was measured using TMS paradigms known as short-interval cortical inhibition
(SICI), cortical silent period (CSP), and intracortical facilitation (ICF). Patients with OCD demonstrated significantly shortened CSP
(po0.001, Cohen?s d ? 0.91) and increased ICF (po0.009, Cohen?s d ? 0.71) compared with healthy subjects. By contrast, there were
no significant deficits in SICI. After excluding patients with OCD and comorbid major depressive disorder (MDD) from the analysis, these
differences remained significant. Our findings suggest that OCD is associated with dysregulation in cortical inhibitory and facilitatory
neurotransmission. Specifically, these findings suggest impairments in GABAB receptor-mediated and NMDA receptor-mediated
neurotransmission. These findings are consistent with previously published genetic studies implicating GABAB, and NMDA transporter
and receptor genes in OCD. It is posited that dysregulation of such mechanisms may lead to the generation and persistence of intrusive
thoughts that form the basis for this disorder
UR - http://www.nature.com/npp/journal/v37/n5/pdf/npp2011300a.pdf
U2 - 10.1038/npp.2011.300
DO - 10.1038/npp.2011.300
M3 - Article
VL - 37
SP - 1144
EP - 1151
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
SN - 0893-133X
IS - 5
ER -